FROECHLICH, GUENDALINA
 Distribuzione geografica
Continente #
AS - Asia 980
EU - Europa 892
NA - Nord America 788
SA - Sud America 103
AF - Africa 27
Totale 2.790
Nazione #
US - Stati Uniti d'America 742
SG - Singapore 361
IT - Italia 355
RU - Federazione Russa 293
VN - Vietnam 223
CN - Cina 184
BR - Brasile 81
HK - Hong Kong 68
GB - Regno Unito 59
DE - Germania 48
BD - Bangladesh 41
FR - Francia 39
NL - Olanda 34
IN - India 32
CA - Canada 24
FI - Finlandia 19
JP - Giappone 19
AR - Argentina 12
KR - Corea 12
CI - Costa d'Avorio 10
MX - Messico 10
PL - Polonia 9
SE - Svezia 9
ZA - Sudafrica 9
ES - Italia 7
IQ - Iraq 6
PH - Filippine 6
TH - Thailandia 5
AT - Austria 4
CR - Costa Rica 4
AE - Emirati Arabi Uniti 3
GT - Guatemala 3
IE - Irlanda 3
LT - Lituania 3
PY - Paraguay 3
UZ - Uzbekistan 3
AL - Albania 2
BE - Belgio 2
CL - Cile 2
EC - Ecuador 2
MY - Malesia 2
PK - Pakistan 2
RO - Romania 2
TN - Tunisia 2
TR - Turchia 2
UA - Ucraina 2
VE - Venezuela 2
AF - Afghanistan, Repubblica islamica di 1
BS - Bahamas 1
BW - Botswana 1
CG - Congo 1
DZ - Algeria 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
HN - Honduras 1
ID - Indonesia 1
IL - Israele 1
JO - Giordania 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
LY - Libia 1
NI - Nicaragua 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
RS - Serbia 1
TC - Turks e Caicos 1
TW - Taiwan 1
UY - Uruguay 1
Totale 2.790
Città #
Singapore 178
Naples 158
San Jose 136
Ashburn 93
Moscow 72
Hong Kong 67
Beijing 56
Ho Chi Minh City 50
Chandler 48
Santa Clara 46
Hanoi 36
Los Angeles 32
Hefei 31
Amsterdam 30
Lauterbourg 20
New York 20
The Dalles 18
Tokyo 15
Millbury 14
Dallas 13
Munich 13
Napoli 13
Frankfurt am Main 12
San Paolo Bel Sito 12
Denver 11
Lawrence 11
Milan 10
Rome 10
Seattle 10
São Paulo 10
Buffalo 9
Seoul 9
Biên Hòa 8
Haiphong 8
Lappeenranta 8
Pune 8
Toronto 8
Warsaw 8
Chicago 7
Da Nang 7
Marano 7
Redondo Beach 7
Boston 6
Helsinki 6
Hải Dương 6
London 6
Tianjin 6
Capaccio 5
Chennai 5
Des Moines 5
Falkenstein 5
Formia 5
Houston 5
Hyderabad 5
Johannesburg 5
Kochi 5
Montreal 5
Nuremberg 5
Wilmington 5
Bologna 4
Brooklyn 4
Council Bluffs 4
Düsseldorf 4
Ercolano 4
Hangzhou 4
Nha Trang 4
Orem 4
Portsmouth 4
San José 4
Stockholm 4
Afragola 3
Arezzo 3
Avellino 3
Baghdad 3
Belo Horizonte 3
Bắc Giang 3
Casalnuovo di Napoli 3
City of London 3
Columbus 3
Jiaxing 3
Memphis 3
Nanjing 3
New Delhi 3
Ottawa 3
Poplar 3
Salt Lake City 3
San Francisco 3
San Vitaliano 3
Tashkent 3
Thái Bình 3
Trentola-Ducenta 3
Washington 3
Abbeville 2
Atlanta 2
Bella Vista 2
Bình Phước 2
Cagliari 2
Campi Bisenzio 2
Can Tho 2
Casavatore 2
Totale 1.555
Nome #
Generation of a novel mesothelin-targeted oncolytic herpes virus and implemented strategies for manufacturing 193
Integrating system biology and intratumor gene therapy by trans-complementing the appropriate co-stimulatory molecule as payload in oncolytic herpes virus 189
Integrity of the antiviral STING-mediated DNA sensing in tumor cells is required to sustain the immunotherapeutic efficacy of herpes simplex oncolytic virus 180
One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1 152
Generation of a retargeted oncolytic herpes virus encoding adenosine deaminase for tumor adenosine clearance 151
Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells 147
Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies. 146
A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells 145
Prime and pull of Tcell responses against cancer-exogenous antigens is effective against CPI-resistant tumors 138
Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling 137
Novel combinations of human immunomodulatory mAbs lacking cardiotoxic effects for therapy of TNBC 135
New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC 134
High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand 134
Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment 131
Immunomodulatory mabs as tools to investigate on cis-interaction of pd-1/pd-l1 on tumor cells and to set up methods for early screening of safe and potent combinatorial treatments 130
Peptide nucleic acid-mediated circularization of target RNA as tool to inhibit translation 128
Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis 125
The common H232 STING allele shows impaired activities in DNA sensing, susceptibility to viral infection, and in monocyte cell function, while the HAQ variant possesses wild-type properties 105
Generation of novel human anti-OX-40 mAbs endowed with different biological properties as tools for cancer therapy 82
Recombineering-based Manufacturing of Engineered Viral Vectors for Research and Therapy 67
Lipid self-assembling nanoparticles as a novel platform for mRNA-based vaccination 32
We ARE boosting translation: AU-rich elements for enhanced therapeutic mRNA translation 30
FKBP5 isoforms shape immune pathways related to tumor tolerance 22
Broadly cross-reactive mRNA COVID-19 vaccine encoding trimeric RBDs and NSP12 mitigates immune imprinting 12
Editorial: Crosstalk in tumor microenvironments: shaping early drug and immunotherapy strategies 4
Totale 2.849
Categoria #
all - tutte 8.467
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.467


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022148 2 3 10 4 7 7 28 11 18 15 19 24
2022/2023146 13 6 2 6 24 18 1 12 25 27 11 1
2023/2024169 4 16 28 18 7 26 1 15 2 25 21 6
2024/2025763 46 20 16 11 29 65 70 42 36 85 278 65
2025/20261.561 136 89 138 142 274 53 142 66 228 115 95 83
2026/202716 16 0 0 0 0 0 0 0 0 0 0 0
Totale 2.849